Valuation: NovoCure Limited

Market Cap 1.81B 1.56B 1.47B 1.34B 2.51B 173B 2.52B 17.5B 6.73B 87.78B 6.78B 6.63B 277B P/E 2026 *
-12.4x
P/E 2027 * -19x
Enterprise Value 1.7B 1.47B 1.39B 1.26B 2.36B 162B 2.37B 16.48B 6.34B 82.66B 6.39B 6.25B 261B EV / Sales 2026 *
2.34x
EV / Sales 2027 * 1.98x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 day+1.04%
1 week-13.55%
Current month-12.12%
1 month-10.76%
3 months-12.77%
6 months+28.61%
Current year+19.95%
1 week 15.1
Extreme 15.1
17.78
1 month 15.1
Extreme 15.1
18.61
Current year 9.82
Extreme 9.82
21.45
1 year 9.82
Extreme 9.82
21.45
3 years 9.82
Extreme 9.82
34.13
5 years 9.82
Extreme 9.82
132.38
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 01/12/2025
Director of Finance/CFO 52 01/01/2025
Chief Tech/Sci/R&D Officer - 17/01/2023
Director TitleAgeSince
Director/Board Member 59 01/01/2012
Chairman 63 01/01/2009
Director/Board Member 64 05/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
30/06/26 Free

Chief Executive Officer

1,905 0.0016%
30/06/26 Free

Head of Human Resources

1,905 0.0016%
30/06/26 Free

General Counsel

1,299 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%-13.55%+27.65%-22.22% 1.81B
-0.02%-1.38%+16.50%+13.78% 12.52B
+1.49%-2.46%+12.13%+16.64% 6.59B
+0.27%-3.37% - - 6.33B
+1.91%-5.00%+22.56%+8.93% 5.51B
+1.23%-3.40%-19.07%+38.52% 5.04B
-0.24%-1.71%-35.10%-24.58% 3.76B
+0.16%+7.01%-1.13%+165.08% 1.78B
+1.46%-3.79%+44.50%-18.11% 1.57B
-1.32%-4.76%-22.63%+36.63% 1.33B
Average +0.59%-3.56%+5.05%+23.85% 4.62B
Weighted average by Cap. +0.63%-3.08%+6.77%+17.73%

Financials

2026 *2027 *
Net sales 726M 625M 592M 537M 1.01B 69.34B 1.01B 7.03B 2.7B 35.28B 2.73B 2.67B 111B 805M 693M 657M 595M 1.12B 76.88B 1.12B 7.8B 3B 39.12B 3.02B 2.96B 124B
Net income -142M -122M -116M -105M -197M -13.57B -198M -1.38B -529M -6.9B -533M -522M -21.81B -84.78M -73.05M -69.17M -62.69M -118M -8.1B -118M -821M -316M -4.12B -318M -311M -13.02B
Net Debt -105M -90.88M -86.05M -78M -146M -10.08B -147M -1.02B -393M -5.13B -396M -387M -16.2B -210M -181M -171M -155M -291M -20.05B -293M -2.03B -782M -10.2B -788M -771M -32.24B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
11/09/26 $15.51 +1.04% 1,127,182
10/09/26 $15.35 -1.79% 1,385,210
09/09/26 $15.63 -7.24% 996,520
08/09/26 $16.85 -6.08% 1,460,201
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
15.51USD
Average target price
27.14USD
Spread / Average Target
+75.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!